CoChat

BCL-2 antagonism sensitizes cytotoxic T cell–resistant HIV reservoirs to elimination ex vivo

Open access
Ren, Yanqin, Huang, Szu Han, Patel, Shabnum, Alberto, Winiffer D. Conce, Magat, Dean, Ahimovic, Dughan, Macedo, Amanda B., Durga, Ryan, Chan, Dora, Zale, Elizabeth, Mota, Talia M., Truong, Ronald, Rohwetter, Thomas, McCann, Chase D., Kovacs, Colin M., Benko, Erika, Wimpelberg, Avery, Cannon, Christopher, Hardy, W. David, Bosque, Alberto, Bollard, Catherine M., Jones, R. Brad · 2020 · Journal of Clinical Investigation
Cited by 124

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

Curing HIV infection will require the elimination of a reservoir of infected CD4+ T cells that persists despite HIV-specific cytotoxic T cell (CTL) responses. Although viral latency is a critical factor in this persistence, recent evidence also suggests a role for intrinsic resistance of reservoir-harboring cells to CTL killing. This resistance may have contributed to negative outcomes of clinical trials, where pharmacologic latency reversal has thus far failed to drive reductions in HIV reservoirs. Through transcriptional profiling, we herein identified overexpression of the prosurvival factor B cell lymphoma 2 (BCL-2) as a distinguishing feature of CD4+ T cells that survived CTL killing. We show that the inducible HIV reservoir was disproportionately present in BCL-2hi subsets in ex vivo CD4+ T cells. Treatment with the BCL-2 antagonist ABT-199 was not sufficient to drive reductions in ex vivo viral reservoirs when tested either alone or with a latency-reversing agent (LRA). However, the triple combination of strong LRAs, HIV-specific T cells, and a BCL-2 antagonist uniquely enabled the depletion of ex vivo viral reservoirs. Our results provide rationale for novel therapeutic approaches targeting HIV cure and, more generally, suggest consideration of BCL-2 antagonism as a means of enhancing CTL immunotherapy in other settings, such as cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci132374

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 124

Metadata

Authors
Ren, Y., Huang, S. H., Patel, S., Alberto, W. D. C., Magat, D., Ahimovic, D., Macedo, A. B., Durga, R., Chan, D., Zale, E., Mota, T. M., Truong, R., Rohwetter, T., McCann, C. D., Kovacs, C. M., Benko, E., Wimpelberg, A., Cannon, C., Hardy, W. D., Bosque, A., Bollard, C. M., & Jones, R. B.
Venue
Journal of Clinical Investigation
Published
2020-04-13
Volume
130
Issue
5
Pages
2542-2559
ISSN
  • 0021-9738 (ISSN-L)
  • 1558-8238
OpenAlex
W3004775388
Cited by
124
References
19
FWCI
7.85
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: BCL-2 antagonism sensitizes cytotoxic T cell–resistant HIV reservoirs to elimination ex vivo. https://app.cochat.ai/papers/10.1172/jci132374
The paper
Ren, Y., Huang, S. H., Patel, S., Alberto, W. D. C., Magat, D., Ahimovic, D., Macedo, A. B., Durga, R., Chan, D., Zale, E., Mota, T. M., Truong, R., Rohwetter, T., McCann, C. D., Kovacs, C. M., Benko, E., Wimpelberg, A., Cannon, C., Hardy, W. D., . . . Jones, R. B. (2020). BCL-2 antagonism sensitizes cytotoxic T cell–resistant HIV reservoirs to elimination ex vivo. Journal of Clinical Investigation. https://doi.org/10.1172/jci132374

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.